An international analysis has found that the higher cost of cancer care delivery in the United States appears to be worthwhile. The greater survival gains experienced by cancer patients generated $598 billion of additional value for those diagnosed between 1983 and 1999. The value of this additional survival was highest for prostate and breast cancer patients.
Abstract: Health Affairs, April 2012.
